Skip to main content

Advertisement

Table 3 Clinicopathological variables and expressions from FGFR1 to FGFR4 in IGC

From: Different clinical significance of FGFR1–4 expression between diffuse-type and intestinal-type gastric cancer

  FGFR1   FGFR2   FGFR3   FGFR4  
Low High p Low High p Low High p Low High p
  n 62 38   36 64   24 76   19 81  
Age (years)
  < 65 32 19 13 0.71 10 22 0.50 7 25 0.73 9 23 0.11
  ≥ 65 68 43 25 26 42 17 51 10 58
Gender
 Female 13 5 8 0.073 3 10 0.37 3 10 1.00 1 12 0.45
 Male 87 57 30 33 54 21 66 18 69
Main location
 Middle or lower 84 53 31 0.61 32 52 0.32 19 65 0.53 15 69 0.50
 Upper 16 9 7 4 12 5 11 4 12
Depth of invasion
 Early (T1) 49 34 15 0.14 22 27 0.069 12 37 0.91 17 32 <0.001
 Advanced (T2/3/4) 51 28 23 14 37 12 39 2 49
LN metastasis
 Negative (N0) 66 42 24 0.64 26 40 0.33 16 50 0.94 17 49 0.016
 Positive (N1/2/3) 34 20 14 10 24 8 26 2 32
Stage
 I 60 40 20 0.24 25 35 0.15 15 45 0.77 18 42 0.001
 II/III/IV 40 22 18 11 29 9 31 1 39
Distant metastasis or recurrence
 Negative 80 53 27 0.080 31 49 0.25 17 63 0.24 19 61 0.01
 Positive 20 9 11 5 15 7 13 0 20
Peritoneal dissemination
 Negative 93 59 34 0.42 34 59 1.00 21 72 0.35 19 74 0.34
 Positive 7 3 4 2 5 3 4 0 7
Hematogenous metastasis
 Negative 90 56 34 1.00 34 56 0.32 22 68 1.00 19 71 0.20
 Positive 10 6 4 2 8 2 8 0 10
HER2 score
 0–1 84 50 34 0.24 30 54 0.89 19 65 0.53 18 66 0.29
 2–3 16 12 4 6 10 5 11 1 15